Compared to a collection of well-established cancer genes on which we performed the same analyses, genomic alterations of NATs are considerably lower (TP53—36%; PTEN—12%; KRAS—9%; MYC—9%; RB1—7%). This evidence concerns the gene MYC and cancer.